Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Embutramide is a potent general anesthetic and sedative agent primarily used in veterinary medicine as a component of euthanasia solutions, most notably **T-61** (also marketed as **Tanax**). It exerts a strong narcotic effect on the central nervous system, specifically targeting and paralyzing the brain's respiratory center to induce rapid respiratory arrest. Due to its high potency and potential for respiratory failure, it is typically formulated in combination with a neuromuscular blocking agent (such as mebezonium iodide) and a local anesthetic (such as tetracaine hydrochloride) to ensure a painless and rapid death in animals. In the United States, embutramide is classified as a **Schedule III** controlled substance under the Controlled Substances Act due to its potential for abuse and its association with human fatalities in cases of accidental poisoning or suicide attempts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on embutramide.